Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

HHS Logo Eagle IconU.S. Department of Health and Human Services

Office of Science and Data Policy (SDP)

The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.

The Office of Science and Data Policy includes several components:

Topic Areas:

  • HHS Data Council
  • Regulatory Impact Analysis
  • Strategic Planning
  • Information Quality Guidelines
  • Prevention and wellness
  • Public health systems and functions
  • Food safety and nutrition
  • Drugs and devices
  • Tobacco control and prevention
  • Biomedical research and development
  • Economic analysis
  • Emergency preparedness, response, and recovery
  • Data and statistical policy
  • Health disparities and vulnerable populations
  • Health information technology
  • Microsimulation
  • Privacy policy

Reports

Displaying 1 - 10 of 171. 10 per page. Page 1.

Advanced Search
Report

Measuring Preparedness for Public Health and Health Care Emergencies: The Current State of Preparedness Metrics in the United States and Considerations for the Future

To help the federal government and STLT jurisdictions better prepare for emergencies, there is a need to understand how prepared different jurisdictions are for various emergencies. However, assessing whether a jurisdiction is prepared for different emergencies is inherently complex and there is a lack of consensus among practitioners and scholars on how to approach preparedness measurement.
Research Summary

FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time

This landing page presents the abstract of a paper published in Health Affairs. The full text of the article is available at: https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2023.00837.
Report

National Action Plan for Combating Antibiotic-Resistant Bacteria Progress Report: Fiscal Year 2022

The evolution of pathogens to resist the drugs used to treat infections is an ongoing threat to public health, animal health, food production, and national security. Globally, a recent analysis estimated that 1.2 million deaths were caused by antibiotic-resistant (AR) bacteria in 2019, making this threat a leading cause of death for people of all ages worldwide.

HHS Implementation Guidance on Data Collection Standards for Race, Ethnicity, Sex, Primary Language, and Disability Status

ASPE Data Point

Linking Medical Product Manufacturing Locations with Natural Hazard Risk: Implications for the Medical Product Supply Chain

This ASPE data point links manufacturer location data with the Federal Emergency Management Agency (FEMA) National Risk Index (NRI), which describes relative risk of experiencing a variety of natural hazards in order to highlight the ways in which natural disasters may pose supply chain vulnerabilities within the U.S.
Environmental Scan

Impact of COVID-19 on Clinical Trials Costs to Patients

This environmental scan, conducted by Mathematica and funded by ASPE, examines the types of direct and direct costs to patients associated with clinical trial participation. It also explores the effect of COVID-19 on costs to patients, including cost implications of clinical trial innovations widely implemented during COVID-19 and other efforts to increase diversity of clinical trials.
ASPE Issue Brief, Report

Transformation of the Clinical Trial Enterprise: Lessons Learned from the COVID-19 Pandemic

In 2023, ASPE launched a research project to understand the impacts of COVID-19 on the clinical trial enterprise and identify key lessons learned.
ASPE Issue Brief

Medical Product Shortages in the United States: Demographic and Geographic Factors and Impacts

Medical product shortages are an ongoing public health concern, with at least 140 products in shortage as of July 2024.We use the Household Pulse Survey to examine how many adults are affected by shortages of critical medical products in the United States.In fall 2023, shortages of medical products impacted about 38.8 million (18 percent) of individuals in the United Stat
ASPE Issue Brief

Impacts of a Nonprofit Membership-Based Pharmaceutical Company on Volume of Drugs Sold and Drug Prices: A Case Study

We report findings of a case study of Civica Rx, a U.S. nonprofit pharmaceutical company whose model is based on long-term hospital membership agreements with minimum volume commitments and buffer stock requirements.Related Products:
Report

The Potential Role of The Nonprofit Pharmaceutical Industry in Addressing Shortages and Increasing Access to Essential Medicines and Low-Cost Medicines

We report findings of a study that described the emerging nonprofit pharmaceutical industry and its commercialization activities to enhance access to affordable and essential drugs, or resiliency in the supply chains of medical products.